Literature DB >> 8634448

Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies.

M J Kersten1, L M Evers, P L Dellemijn, H van den Berg, P Portegies, R Q Hintzen, R A van Lier, A E von dem Borne, R H van Oers.   

Abstract

Diagnosis of meningeal localization of lymphoid malignancies by means of cytologic examination of the cerebrospinal fluid (CSF) can be difficult. Thus far no reliable CSF tumor markers have been identified. CD27 is a transmembrane disulfide-linked 55-kD homodimer present on most peripheral blood T cells and on a subset of B cells. CD27 is also expressed on human malignant B cells and high levels of soluble CD27 can be present in the serum of patients with B-cell malignancies. The aim of this study is to determine prospectively the diagnostic value of CSF sCD27 as a tumor marker in patients with meningeal localization of lymphoid malignancies. CSF sCD27 levels were determined by sandwich enzyme-linked immunosorbent assay. The optimal cut-off value using receiver operator characteristics curves was found to be 10 U/mL. sCD27 levels were normal in all 50 control patients (lumbar disc protrusion) and in 39 of 40 samples obtained from patients with either solid tumors or acute myeloid leukemia. Of 104 CSF samples from 70 children with acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma (NHL) undergoing routine central nervous system (CNS) staging, sCD27 was false positive and false negative in only one sample each. In 70 samples from 45 patients suspected of meningeal localization of ALL or NHL, the sCD27 test had an excellent sensitivity (100%) and specificity (82%). In 7 patients with positive CSF studied longitudinally, sCD27 levels correlated very well with remission and relapse. sCD27 levels were not nonspecifically increased by the administration of cytostatic drugs. Finally, sCD27 was also elevated in the 4 patients studied with primary central nervous system lymphoma (PCNSL). CSF sCD27 is a promising tumor marker in patients with either meningeal localization of lymphoid malignancies or PCNSL, and can be useful in the differential diagnosis of CNS involvement by either lymphoid malignancies or solid tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8634448

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

Review 1.  Leukemia and the nervous system.

Authors:  Marc C Chamberlain
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

Review 2.  In situ hybridization: a possible diagnostic aid in leptomeningeal metastasis.

Authors:  R J van Oostenbrugge; A H Hopman; F C Ramaekers; A Twijnstra
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

3.  Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum.

Authors:  John B Welsh; Lisa M Sapinoso; Suzanne G Kern; David A Brown; Tao Liu; Asne R Bauskin; Robyn L Ward; Nicholas J Hawkins; David I Quinn; Pamela J Russell; Robert L Sutherland; Samuel N Breit; Christopher A Moskaluk; Henry F Frierson; Garret M Hampton
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-06       Impact factor: 11.205

Review 4.  Leukemic and lymphomatous meningitis: incidence, prognosis and treatment.

Authors:  Marc C Chamberlain; Craig Nolan; Lauren E Abrey
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

5.  Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).

Authors:  Francisco-Javier Peñalver; Juan-Manuel Sancho; Adolfo de la Fuente; María-Teresa Olave; Alejandro Martín; Carlos Panizo; Elena Pérez; Antonio Salar; Alberto Orfao
Journal:  Haematologica       Date:  2016-10-20       Impact factor: 9.941

6.  Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).

Authors:  Takashi Sasayama; Satoshi Nakamizo; Masamitsu Nishihara; Atsufumi Kawamura; Hirotomo Tanaka; Katsu Mizukawa; Shigeru Miyake; Masaaki Taniguchi; Kohkichi Hosoda; Eiji Kohmura
Journal:  Neuro Oncol       Date:  2011-12-12       Impact factor: 12.300

Review 7.  Secondary central nervous system lymphoma.

Authors:  Naoto Tomita; Fumio Kodama; Heiwa Kanamori; Shigeki Motomura; Yoshiaki Ishigatsubo
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

8.  MicroRNAs as Potential Biomarkers for Diagnosing Cancers of Central Nervous System: a Meta-analysis.

Authors:  Dong Wei; Qun Wan; Li Li; Haifeng Jin; Yonghong Liu; Yangang Wang; Guangyun Zhang
Journal:  Mol Neurobiol       Date:  2014-08-01       Impact factor: 5.590

Review 9.  Modern cerebrospinal fluid analyses for the diagnosis of diffuse large B-cell lymphoma of the CNS.

Authors:  Alexander Baraniskin; Roland Schroers
Journal:  CNS Oncol       Date:  2014-01

Review 10.  Meningeosis leukaemica in adult acute lymphoblastic leukaemia.

Authors:  N Gökbuget; D Hoelzer
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.